Glaxo JV Wins FDA Go-Ahead, Chesapeake Drops Four Execs, and 3 More Hot Stocks

GlaxoSmithKline (NYSE:GSK): Glaxo’s joint venture, ViiV Healthcare, has won Food and Drug Administration approval for its once-daily HIV pill Tivicay, which was shown to reduce the HIV virus to undetectable levels in more people than Gilead’s (NASDAQ:GILD) Atripla, the world’s top-selling treatment for the segment. Glaxo has a 76.5 percent holding in ViiV, while Pfizer has 13.5 percent, and Japan’s Shionogi has 10 percent.

gsk-08132013